Download PDF (external access)

Gynecologic Oncology

Publication date: 2015-02-01
Volume: 136 Pages: 246 - 53
Publisher: Academic Press

Author:

Matulonis, Ursula
Vergote, Ignace ; Backes, Floor ; Martin, Lainie P ; McMeekin, Scott ; Birrer, Michael ; Campana, Frank ; Xu, Yi ; Egile, Coumaran ; Ghamande, Sharad

Keywords:

Science & Technology, Life Sciences & Biomedicine, Oncology, Obstetrics & Gynecology, Endometrial cancer, PI3K inhibitors, MAMMALIAN TARGET, CANCER, MUTATIONS, TRIAL, TEMSIROLIMUS, PATHWAY, PIK3CA, PTEN, COMBINATION, EVEROLIMUS, Aged, Aged, 80 and over, Antineoplastic Agents, Endometrial Neoplasms, Female, Humans, Middle Aged, Neoplasm Recurrence, Local, Phosphoinositide-3 Kinase Inhibitors, Protein Kinase Inhibitors, Quinoxalines, Sulfonamides, 1112 Oncology and Carcinogenesis, 1114 Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, 3202 Clinical sciences, 3211 Oncology and carcinogenesis, 3215 Reproductive medicine

Abstract:

Patients with endometrial carcinoma who progress after first-line chemotherapy have a poor prognosis. Phosphoinositide 3-kinase (PI3K) inhibitors are investigational treatment options in this setting. This study evaluated the efficacy and safety of the PI3K inhibitor pilaralisib (SAR245408; XL147) in advanced or recurrent endometrial carcinoma.